Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Anesthetic Preconditioning as Endogenous Neuroprotection in Glaucoma.

Chou TH, Musada GR, Romano GL, Bolton E, Porciatti V.

Int J Mol Sci. 2018 Jan 13;19(1). pii: E237. doi: 10.3390/ijms19010237.

2.

TGF-β1 prevents rat retinal insult induced by amyloid-β (1-42) oligomers.

Fisichella V, Giurdanella G, Platania CB, Romano GL, Leggio GM, Salomone S, Drago F, Caraci F, Bucolo C.

Eur J Pharmacol. 2016 Sep 15;787:72-7. doi: 10.1016/j.ejphar.2016.02.002. Epub 2016 Feb 2.

PMID:
26845696
3.

Effects of Topical Fucosyl-Lactose, a Milk Oligosaccharide, on Dry Eye Model: An Example of Nutraceutical Candidate.

Bucolo C, Musumeci M, Salomone S, Romano GL, Leggio GM, Gagliano C, Reibaldi M, Avitabile T, Uva MG, Musumeci S, Drago F.

Front Pharmacol. 2015 Nov 18;6:280. doi: 10.3389/fphar.2015.00280. eCollection 2015.

4.

MicroRNA target prediction in glaucoma.

Romano GL, Platania CB, Forte S, Salomone S, Drago F, Bucolo C.

Prog Brain Res. 2015;220:217-40. doi: 10.1016/bs.pbr.2015.04.013. Epub 2015 Jun 30. Review.

PMID:
26497793
5.

Effects of novel hybrids of caffeic acid phenethyl ester and NSAIDs on experimental ocular inflammation.

Pittalà V, Salerno L, Romeo G, Siracusa MA, Modica MN, Romano GL, Salomone S, Drago F, Bucolo C.

Eur J Pharmacol. 2015 Apr 5;752:78-83. doi: 10.1016/j.ejphar.2015.02.012. Epub 2015 Feb 19.

PMID:
25704612
6.

Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles.

Leonardi A, Bucolo C, Romano GL, Platania CB, Drago F, Puglisi G, Pignatello R.

Int J Pharm. 2014 Aug 15;470(1-2):133-40. doi: 10.1016/j.ijpharm.2014.04.061. Epub 2014 May 2.

PMID:
24792979
7.

Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation.

Bucolo C, Marrazzo G, Platania CB, Romano GL, Drago F, Salomone S.

J Pharm Pharmacol. 2014 Jul;66(7):954-60. doi: 10.1111/jphp.12224. Epub 2014 Feb 12.

PMID:
24697218

Supplemental Content

Loading ...
Support Center